Arkis BioSciences, a Knoxville, Tenn.-based provider of cerebrospinal fluid treatments for the neurosurgical market, secured $3.4m in Series A funding.
The round was led by Innova Memphis, followed by Angel Capital Group, the Lighthouse Fund, and other private investors.
The company intends to use the funds to accelerate the commercialization of its less-invasive neurosurgical instrumentation and the market release of its in-licensed Endexo® technology.
Led by Chad Seaver, CEO, Arkis BioSciences offers surgical tools and implantables for advancing the treatments of intracranial hypertension arising from traumatic brain injury, hemorrhagic stroke, hydrocephalus, and similar disorders. The company’s offerings include: the Tunneling Guidewire™, which allows for less invasive ventriculoperitoneal shunt procedures; and Endexo® anti-thrombogenic catheters, which are slated for addressing catheter obstructions for more durable treatments.